References to Asensio Reports on Zonagen and Vivus
from News Media and Court Documents
With Non-Working Links to Zonagen Reports


Asensio claims that he has never retracted a single statement.  He doesn't just make the claim in idle conversation.  He has made it under oath--for instance, in a sworn affidavit filed in the South Carolina litigation (where he was found to have committed securities fraud.) 

So if Asensio has never retracted a single word--as he insists--where are his reports on Zonagen and Vivus?  Any chance he removed them to settle litigation, contrary to his claims?   After all, how many publicly traded corporations have sued a three-person operation consisting of a principal,  a research assistant, and a secretary because they were looking for serious cash?   Probably far fewer than have sued to stop lies and innuendo.

No one but Asensio and parties to the litigation know whether the reports were removed to settle litigation--contrary to Asensio's insistence. We know what we think and leave it to you to draw your own conclusion.

Below are some press references to his reports on Zonagen and Vivus, with non-working links to his now-removed Zonagen reports.  You have to ask why Asensio would remove such influential work, and again, we suggest the answer is obvious.
However, reason for skepticism abounded. Well-known short-seller Manuel Asensio issued a series of negative reports in support of his "strong sell" recommendation. In a typical note, Asensio charged that, "Vasomax's secret formulation is merely and simply nothing more than plain 45 year old, generic phentolamine."


a "strong sell" recommendation for Zonagen stock and accompanying report issued November 18, 1997 by Asensio & Co., an institutional investment banking company, and a similar Asensio report issued January 9, 1998.

3. On December 10, 1997, the investment community was shocked by the announcement that the Company would miss fourth quarter revenue goals by as much as 25%, and by the announcement by Asensio & Company the same day that not only did their study of MUSE not yield the same favorable results that Vivus was reporting, but that there were concerns about the accuracy of the product sales figures Vivus had been reporting. 

7. Defendants' plan, scheme and common course of conduct to inflate the price of Vivus stock was successful. When the Company's failure to meet revenue projections and the problems disclosed by the Asensio & Company study were finally disclosed, the price of Vivus stock plummeted. As a result, Vivus shareholders suffered millions of dollars in damages.